BG105155A - Аденозинови производни - Google Patents

Аденозинови производни

Info

Publication number
BG105155A
BG105155A BG105155A BG10515501A BG105155A BG 105155 A BG105155 A BG 105155A BG 105155 A BG105155 A BG 105155A BG 10515501 A BG10515501 A BG 10515501A BG 105155 A BG105155 A BG 105155A
Authority
BG
Bulgaria
Prior art keywords
adenosine derivatives
adenosine
derivatives
solvates
agonist
Prior art date
Application number
BG105155A
Other languages
English (en)
Other versions
BG65064B1 (bg
Inventor
David Bays
Richard COUSINS
Hazel Dyke
Colin Eldred
Brian JUDKINS
Martin Pass
Andrew Pennell
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of BG105155A publication Critical patent/BG105155A/bg
Publication of BG65064B1 publication Critical patent/BG65064B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Съединенията и техни соли и солвати, по-специалнофизиологично приемливи солвати и соли, имат формула, в която Y, Z и W са хетероатоми. Съединенията са агонисти на рецептора на аденозин А1.
BG105155A 1998-06-23 2001-01-15 Аденозинови производни BG65064B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9813554.4A GB9813554D0 (en) 1998-06-23 1998-06-23 Chemical compounds

Publications (2)

Publication Number Publication Date
BG105155A true BG105155A (bg) 2001-09-28
BG65064B1 BG65064B1 (bg) 2007-01-31

Family

ID=10834247

Family Applications (1)

Application Number Title Priority Date Filing Date
BG105155A BG65064B1 (bg) 1998-06-23 2001-01-15 Аденозинови производни

Country Status (40)

Country Link
US (2) US6492348B1 (bg)
EP (2) EP1447407A1 (bg)
JP (2) JP3378240B2 (bg)
KR (1) KR100612797B1 (bg)
CN (2) CN1616459A (bg)
AP (1) AP2000002014A0 (bg)
AR (1) AR018917A1 (bg)
AT (1) ATE277941T1 (bg)
AU (1) AU758018B2 (bg)
BG (1) BG65064B1 (bg)
BR (1) BR9911498A (bg)
CA (1) CA2335520C (bg)
CO (1) CO5040216A1 (bg)
DE (1) DE69920697T2 (bg)
EA (1) EA003828B1 (bg)
EE (1) EE04853B1 (bg)
ES (1) ES2226399T3 (bg)
GB (1) GB9813554D0 (bg)
GE (1) GEP20032958B (bg)
HK (1) HK1034978A1 (bg)
HR (1) HRP20000896B1 (bg)
HU (1) HUP0102453A3 (bg)
ID (1) ID27484A (bg)
IL (2) IL140284A0 (bg)
IS (1) IS5773A (bg)
MY (1) MY122481A (bg)
NO (1) NO318788B1 (bg)
NZ (1) NZ508915A (bg)
OA (1) OA11574A (bg)
PE (1) PE20000704A1 (bg)
PL (1) PL194087B1 (bg)
PT (1) PT1090019E (bg)
RS (1) RS50042B (bg)
SI (1) SI1090019T1 (bg)
SK (1) SK19582000A3 (bg)
TR (1) TR200100449T2 (bg)
TW (1) TW541312B (bg)
UA (1) UA64794C2 (bg)
WO (1) WO1999067262A1 (bg)
ZA (1) ZA200007514B (bg)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
WO2001064202A2 (en) * 2000-03-01 2001-09-07 Euro-Celtique S.A. Tramadol for the treatment of functional gastrointestinal disorders
GB0106867D0 (en) 2001-03-20 2001-05-09 Glaxo Group Ltd Process
US20040162422A1 (en) * 2001-03-20 2004-08-19 Adrian Hall Chemical compounds
GB0115182D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Medicaments
GB0115178D0 (en) * 2001-06-20 2001-08-15 Glaxo Group Ltd Compounds
US7157440B2 (en) 2001-07-13 2007-01-02 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
US7713946B2 (en) 2002-07-11 2010-05-11 Cv Therapeutics, Inc. Partial and full agonists A1 adenosine receptors
US6946449B2 (en) 2001-07-13 2005-09-20 Cv Therapeutics, Inc. Partial and full agonists of A1 adenosine receptors
CN101392012A (zh) 2002-02-19 2009-03-25 Cv医药有限公司 A1腺苷受体的部分和全促效药
WO2003106475A2 (en) * 2002-06-17 2003-12-24 Glaxo Group Limited Process
RU2340623C2 (ru) * 2002-08-15 2008-12-10 Си Ви Терапьютикс, Инк. Частичные и полные агонисты аденозиновых рецепторов a1
WO2004055032A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Adenosine derivative in polymorph v form
AU2003292255A1 (en) * 2002-12-18 2004-07-09 Glaxo Group Limited Polymorph
WO2004055033A1 (en) * 2002-12-18 2004-07-01 Glaxo Group Limited Adenosine derivative in polymorph iv form
WO2004069185A2 (en) 2003-02-03 2004-08-19 Cv Therapeutics Inc. Partial and full agonists of a1 adenosine receptors
WO2005053712A1 (en) * 2003-12-02 2005-06-16 Glaxo Group Limited Use of adenonsine derivatives for treating dyslipidemia, obesity, cardiovascular risk factors, metabolic syndrome, polycystic ovary syndrome, niddm
GT200500281A (es) * 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
MY146645A (en) * 2006-04-21 2012-09-14 Novartis Ag Purine derivatives for use as adenosin a2a receptor agonists
GB0607954D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607950D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607944D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607953D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
GB0607948D0 (en) * 2006-04-21 2006-05-31 Novartis Ag Organic compounds
EP1889846A1 (en) 2006-07-13 2008-02-20 Novartis AG Purine derivatives as A2a agonists
EP1903044A1 (en) * 2006-09-14 2008-03-26 Novartis AG Adenosine Derivatives as A2A Receptor Agonists
BRPI0718792A2 (pt) * 2006-11-10 2013-12-03 Novartis Ag Compostos orgânicos
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CN101712709A (zh) * 2008-10-06 2010-05-26 中国医学科学院药物研究所 三乙酰基-3-羟基苯基腺苷及其调血脂的用途
WO2013120078A1 (en) * 2012-02-11 2013-08-15 Academia Sinica Methods and compositions for treating pain
WO2016135582A1 (en) * 2015-02-24 2016-09-01 Pfizer Inc. Substituted nucleoside derivatives useful as anticancer agents
CN108864099A (zh) * 2018-09-08 2018-11-23 湖北荆洪生物科技股份有限公司 一种高纯6-糠氨基嘌呤的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4962194A (en) * 1987-04-02 1990-10-09 Warner-Lambert Company Method of preparing 51,N6-disubstituted adenosines from inosines
US5646128A (en) * 1989-09-15 1997-07-08 Gensia, Inc. Methods for treating adenosine kinase related conditions
US5244896A (en) * 1990-09-14 1993-09-14 Marion Merrell Dow Inc. Carbocyclic adenosine analogs useful as immunosuppressants
DK62592D0 (bg) * 1992-05-14 1992-05-14 Novo Nordisk As
GB9301000D0 (en) * 1993-01-20 1993-03-10 Glaxo Group Ltd Chemical compounds
JP3696882B2 (ja) * 1993-07-23 2005-09-21 メレル ファーマス−ティカルズ インコーポレイテッド プロ炎症性サイトカインの選択的抑制剤として有用な新規な９−ｎ−二環式ヌクレオシド剤
AU3255097A (en) * 1996-07-05 1998-02-02 Novo Nordisk A/S Novel (n)-alkoxyadenine derivatives acting as cytokine inhibitors
UA51716C2 (uk) * 1996-07-08 2002-12-16 Авентіс Фармасьютікалз Продактс Інк. Сполуки, що мають гіпотензивну, кардіопротекторну, анти-ішемічну та антиліполітичну властивості, фармацевтична композиція та способи лікування
AU4377397A (en) * 1996-10-14 1998-05-11 Novo Nordisk A/S Novel therapeutically active adenosine derivatives
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (sh) 1998-01-31 2003-01-31 Glaxo Group Limited Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
AR017457A1 (es) 1998-02-14 2001-09-05 Glaxo Group Ltd Compuestos derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol, procesos para su preparacion, composiciones que los contienen y su uso en terapia para el tratamiento de enfermedades inflamatorias.
GB9813554D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
CN1616459A (zh) 2005-05-18
EP1090019B1 (en) 2004-09-29
PT1090019E (pt) 2005-01-31
HK1034978A1 (en) 2001-11-09
US20030096788A1 (en) 2003-05-22
UA64794C2 (en) 2004-03-15
NZ508915A (en) 2003-09-26
KR100612797B1 (ko) 2006-08-17
EE04853B1 (et) 2007-06-15
CA2335520C (en) 2007-02-20
DE69920697T2 (de) 2005-02-24
CN1314910A (zh) 2001-09-26
CN1202118C (zh) 2005-05-18
AU4514699A (en) 2000-01-10
PL345089A1 (en) 2001-12-03
JP3378240B2 (ja) 2003-02-17
CA2335520A1 (en) 1999-12-29
IS5773A (is) 2000-12-15
TW541312B (en) 2003-07-11
AP2000002014A0 (en) 2000-12-31
WO1999067262A1 (en) 1999-12-29
CO5040216A1 (es) 2001-05-29
EA200001222A1 (ru) 2001-08-27
EP1447407A1 (en) 2004-08-18
NO318788B1 (no) 2005-05-09
NO20006520L (no) 2001-02-14
HRP20000896A2 (en) 2001-12-31
JP2002518509A (ja) 2002-06-25
SK19582000A3 (sk) 2001-11-06
DE69920697D1 (de) 2004-11-04
HUP0102453A2 (hu) 2002-04-29
SI1090019T1 (en) 2005-02-28
IL140284A0 (en) 2002-02-10
HRP20000896B1 (en) 2006-03-31
BR9911498A (pt) 2001-03-20
AU758018B2 (en) 2003-03-13
EE200000784A (et) 2002-04-15
AR018917A1 (es) 2001-12-12
NO20006520D0 (no) 2000-12-20
JP2003040891A (ja) 2003-02-13
HUP0102453A3 (en) 2002-10-28
US6492348B1 (en) 2002-12-10
ATE277941T1 (de) 2004-10-15
GB9813554D0 (en) 1998-08-19
GEP20032958B (en) 2003-04-25
RS50042B (sr) 2008-11-28
TR200100449T2 (tr) 2001-08-21
ES2226399T3 (es) 2005-03-16
EP1090019A1 (en) 2001-04-11
PL194087B1 (pl) 2007-04-30
MY122481A (en) 2006-04-29
US6677316B2 (en) 2004-01-13
KR20010083067A (ko) 2001-08-31
ID27484A (id) 2001-04-12
EA003828B1 (ru) 2003-10-30
IL140284A (en) 2006-04-10
BG65064B1 (bg) 2007-01-31
PE20000704A1 (es) 2000-08-03
ZA200007514B (en) 2002-01-23
OA11574A (en) 2004-07-21
YU82800A (sh) 2003-04-30

Similar Documents

Publication Publication Date Title
BG105155A (bg) Аденозинови производни
WO1999024449A3 (en) Adenosine a1 receptor agonists
RS49688B (sr) Novi derivat 3-aril-2- hidroksipropionske kiseline (i)
WO1999024450A3 (en) Adensine a1 receptor agonists
AP2001002066A0 (en) Substituted oxazoles and thiazoles derivatives at hPPAR gamma and hPPAR alpha activators
MX9700696A (es) Compuestos heterociclicos, utiles como productores de efecto aloesterico en receptores muscarinicos.
BG104670A (bg) 4- (2-кето-1-бензимидазолинил) пиперидинови съединения като orl1-рецепторни агонисти
HU9700069D0 (en) Heterocyclic tachykinine-receptor antagonists
HK1099292A1 (en) Piperazinylpyrazine compounds as agonist or antagonist of serotonin 5ht-2 receptor
HK1054930A1 (en) PyrroloÄ2,3-dÜpyrimidine compounds as immunosuppressive agents
HK1069395A1 (en) Phthalazinone derivatives 2,3
AP9801312A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist.
SE9901462D0 (sv) Novel compound
GB9718903D0 (en) Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents
AU9281198A (en) Benzofuran derivatives
HK1039124A1 (en) Phthalzaine derivatives phosphodiesterase 4 inhibitors.
CA2206122A1 (en) Arylacrylamide derivatives
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
DK0952154T3 (da) N-acyl- og N-aroylaralkylamider
BG104575A (bg) Инхибитори на металопротеазите на матрикса
BG105539A (bg) Елетриптан хидробромид монохидрат
JO2065B1 (en) Tri-azin compounds
YU83100A (sh) Fkbp inhibitori
GB9811050D0 (en) Pyrazoles
EP1203763A3 (de) Beta-Hydroxyalkylamide, Verfahren zu ihrer Herstellung und deren Verwendung